Pacira BioSciences, Inc. is a biopharmaceutical company focused on developing and commercializing non-opioid pain therapies for postsurgical, chronic, and musculoskeletal pain. The company’s commercial portfolio includes EXPAREL, a long-acting local analgesic for postsurgical pain; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and iovera, a handheld cryoanalgesia device for non-pharmacological nerve blocks. Pacira is advancing a pipeline that includes PCRX-201, a gene therapy candidate for knee osteoarthritis, utilizing its proprietary high-capacity adenovirus vector platform. The company operates through its California-based subsidiary Pacira Pharmaceuticals, Inc., and has acquired MyoScience, Inc., Flexion Therapeutics, Inc., and GQ Bio Therapeutics GmbH to expand its capabilities. Pacira serves markets in the United States, the European Union, and Canada, with products approved or cleared for use in these regions. The company was founded in 2006.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage pacira.com
Sector Healthcare IR page investor.pacira.com
Tags
non-opioid pain management, local anesthetics, corticosteroid injections, cryoanalgesia, gene therapy, osteoarthritis, postsurgical pain, musculoskeletal pain, drug delivery systems, medical devices, EXPAREL, ZILRETTA, iovera, PCRX-201, Pacira Pharmaceuticals Inc., MyoScience Inc., Flexion Therapeutics Inc., GQ Bio Therapeutics GmbH, HCAd vector platform, pMVL drug delivery technology
Press page —

Metrics

Valuation  
Market cap $ 1.449B
Market cap (USD) $ 1.449B
P/E 38.64
PEG —
P/BV 2.03
P/S 1.95
P/OCF 8.19
P/FCF 8.57
Dividend yield —
Turnover / mcap —
Returns  
ROE 0.96%
ROI 0.66%
ROIC 0.90%
Profit margin 0.97%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -23.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 41.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 37
Quality score 17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 726.411M 700.966M 674.978M 666.823M 538.966M 426.614M 418.926M 332.427M 286.63M 276.371M 248.997M 197.668M 85.551M 39.084M 15.689M 14.562M 15.006M
Net profit 7.034M -99.56M 41.955M 15.909M 41.98M 145.523M -11.016M -471K -42.611M -37.949M 1.856M -13.716M -63.909M -52.281M -43.328M -27.149M -31.707M
Free cash flow 136.661M 178.753M 139.488M 115.198M 79.851M 39.231M 60.361M 34.356M -1.481M 8.744M -12.274M 3.58M -56.01M -88.387M -37.167M -31.65M -26.347M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 25.88 18.84 33.74 38.61 60.17 59.84 45.3 43.02 45.65 32.3 76.79 88.66 57.49 17.45 6.5 — —
Price performance 12m 0.37 -0.44 -0.13 -0.36 0.01 0.32 0.05 -0.06 0.41 -0.58 -0.13 0.54 2.29 1.68 — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 29.9M 31.7M 38M 47.5M 53M 96.3M 98.4M 106M 113M 124M
↳ YoY growth +15.8% +5.7% +20.0% +25.1% +11.6% +81.6% +2.2% +7.3% +7.3% +9.5%
↳ 5y CAGR +69.9% +48.7% +21.1% +16.3% +15.5% +26.3% +25.5% +22.7% +19.0% +18.5%
Borrowings, current (USD) 119M — — — — — — — 202M 0.00
Borrowings, non-current (USD) — — — — — — — — 384M 372M
Lease liabilities (USD) — — 0.00 45.9M 78.5M 79.6M 73.9M 63.6M 53.5M 46M
Cash and deposits (USD) 35.9M 54.1M 133M 78.2M 100M 586M 104M 153M 277M 159M
Intangible assets (USD) 0.00 — 0.00 104M 96.5M 624M 541M 483M 426M 368M
Right-of-use assets (USD) — — 0.00 38.1M 74.5M 76.4M 70.9M 61M 49.2M 41.8M
Net debt (borrowings + leases - cash) (USD) 82.6M — — — — — — — 362M 260M
Cash flow detail
Operating cash flow (USD) 33.5M 17.8M 48.9M 70.5M 77M 126M 145M 155M 189M 152M
Purchases of property, plant and equipment (USD) -24.7M -19.3M -14.5M -10.2M -37.8M -45.9M -30.1M -15.2M -10.6M -15.3M
Change in receivables (cash effect) (USD) -4.08M -1.72M -6M -8.52M -5.52M -10.4M -2.08M -7.16M -7.75M -10.7M
Change in inventories (cash effect) (USD) 30.4M -10.1M -7.16M -8.03M -6.35M -4.47M 2.49M -8.29M -20.9M -27.6M
Change in payables (cash effect) (USD) 710,000 9.36M -573,000 -1.82M -3.31M -10.3M 6.27M 916,000 3.08M -5.6M
Share buybacks (cash effect) (USD) — — — — — — 0.00 0.00 -25M -148M
Interest paid (cash effect) (USD) -3.85M -6.9M -8.21M -8.2M -7.21M -7M -33.3M -27.6M -15.4M -15.2M
Income taxes paid (cash effect) (USD) -247,000 -129,000 -128,000 -863,000 -2.42M -3.22M -7.4M -4.37M -11M -9.01M
Share-based compensation (USD) 31.2M 31.6M 31.7M 33.7M 39.9M 42.2M 48.1M 47.9M 51.2M 57.5M
Operating cash flow before change in receivables (USD) 37.5M 19.5M 54.9M 79M 82.5M 136M 147M 162M 197M 163M
Free cash flow (OCF - PPE - intangibles) (USD) 8.74M -1.48M 34.4M 60.4M 39.2M 79.9M 115M 139M 179M 137M
Income detail
Research and development expense (USD) 45.7M 57.3M 55.7M 72.1M 59.4M 55.5M 84.8M 76.3M 81.6M 117M
↳ 5y CAGR +25.2% +42.0% +20.9% +30.9% +15.7% +4.0% +8.2% +6.5% +2.5% +14.6%
Total comprehensive income (USD) -37.9M -43M -297,000 -10.4M 146M 41.8M 15.4M 42.6M -99.5M 11M
Comprehensive income to owners (USD) -37.9M -43M -297,000 -10.4M 146M 41.8M 15.4M 42.6M -99.5M 11M
Reported Mar 1, 2017 Feb 28, 2018 Aug 8, 2019 Feb 21, 2020 Mar 1, 2021 Feb 28, 2022 Feb 27, 2025 Feb 27, 2025 Nov 6, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Supplemental Indenture

In connection with the consummation of the Merger (as defined below), the Company and Computershare Trust Company, National Association (the “Trustee”), entered into a First Supplemental Indenture (the “Supplemental Indenture”), dated as of November 17, 2026, which amends and supplements the Indenture (the “Original Indenture” and, together with the Supplemental Indenture, the “Indenture”), dated as of May 14, 2024, by and between the Company and the Trustee, governing the Company’s 2.125% Convertible Senior Notes due 2029 (the “Notes”), of which $287.5 million in aggregate principal amount is outstanding as of the date hereof.

As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company’s U.S. Patent No. 11,033,495 was issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends the Company’s royalty obligations under the agreement until 2041. The Company believes that the royalty period under the agreement ended on December 24, 2021 with the expiration of U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, the Company filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241).

Pacira BioSciences, Inc. — Regulation FD Disclosure Bull 9 Bear 0 Takeover offer

As previously disclosed, on October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company” or “Pacira”), entered into the Agreement and Plan of Merger (the “Merger Agreement”) with Viatris Inc., a Delaware corporation (“Viatris”), and Peach Purchaser Sub Inc., a Delaware corporation and a wholly owned subsidiary of Viatris (“Purchaser”), pursuant to which, among other things, on October 30, 2026, Purchaser commenced a tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the “Shares”), of the Company for $36.50 per Share, in cash, net of applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Merger Agreement.

Prompts

Pacira BioSciences, Inc. (ticker PCRX), listed in United States.

Company History

Date Change Detail
Apr 15, 2019 Renamed PACIRA PHARMACEUTICALS, INC. → PACIRA BIOSCIENCES, INC.

ETFs Holding Pacira BioSciences, Inc.

ETF Weight in ETF Shares Market value As of
DSMC 0.53% 26,943 $ 683.544K Jun 30, 2026
SQLV 0.43% 4,879 $ 123.78K Jun 30, 2026
FTKI 0.33% 2,277 $ 83.065K Nov 16, 2026
SAGP 0.21% 6,385 $ 161.987K Jun 30, 2026
SEIS 0.15% 35,381 $ 897.616K Jun 30, 2026
VFVA 0.12% 42,794 $ 1.108M Aug 31, 2026
IVSS 0.11% 1,167 $ 29.607K Jun 30, 2026
AVUV 0.11% 945,935 $ 34.508M Nov 16, 2026
VFMF 0.11% 41,004 $ 1.062M Aug 31, 2026
PSC 0.10% 89,673 $ 2.275M Jun 30, 2026
AVSC 0.08% 67,688 $ 2.469M Nov 16, 2026
FSEV 0.08% 210 $ 5,327.70 Jun 30, 2026
FESM 0.07% 153,129 $ 3.885M Jun 30, 2026
RESM 0.04% 65 $ 1,649.05 Jun 30, 2026
VFQY 0.04% 7,883 $ 204.17K Aug 31, 2026
DFSV 0.03% 234,926 $ 8.565M Nov 12, 2026
DXUV 0.01% 20,074 $ 731.898K Nov 12, 2026
AVUS 0.01% 25,249 $ 921.084K Nov 16, 2026
AVSU 0.01% 1,762 $ 64.278K Nov 16, 2026
DFAC 0.01% 149,358 $ 5.446M Nov 12, 2026
EBI 0.00% 315 $ 8,158.50 Aug 31, 2026
DFUV 0.00% 866 $ 31.574K Nov 12, 2026